Targeting mitotic kinesin KIF20A: A differentiation-based therapeutic strategy for glioblastoma stem/progenitor cells
Runxiang Qiu1, Alejandra Velazquez Ojeda1, Cesar Gonzalez1
1Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
Abstract:
Glioblastoma multiforme (GBM) remains refractory to current treatment modalities. Differentiation-based approaches, which force cancer stem/progenitor cells to exit the cell cycle and adopt terminal fates, offer an alternative therapeutic strategy. Cell fate regulators operating during stem/progenitor cell divisions integrate proliferative and anti-proliferative cues and represent particularly attractive points of intervention. Here, we investigated the therapeutic potential of targeting mitotic kinesin KIF20A in GBM stem/progenitor cells. KIF20A is a crucial component of cytokinetic machinery and cooperates with a network of cell fate regulators to balance proliferative and differentiative divisions in neural stem/progenitor cells (NSPCs). Using complementary in vitro and in vivo models, including 2D cultures, 3D organoids, and intracranial xenografts, we show that inhibition of KIF20A drives cell cycle exit and induces a postmitotic/differentiated state in GBM stem/progenitor cells, resulting in a marked suppression of proliferation. Together, these findings establish KIF20A as a key vulnerability in GBM and a promising target for differentiation-based intervention.
Insights
Targeting KIF20A in glioblastoma stem cells forces them to differentiate and stop dividing. This research identifies KIF20A as a promising target for new glioblastoma multiforme (GBM) therapies.
Area of Science:
- Neuro-oncology
- Cancer Stem Cell Biology
- Cell Cycle Regulation
Background:
- Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with limited treatment options.
- Cancer stem cells (CSCs) drive GBM growth and recurrence, making them a critical therapeutic target.
- Differentiation therapy aims to force CSCs to exit the cell cycle and mature, halting tumor proliferation.
Purpose of the Study:
- To investigate the therapeutic potential of targeting mitotic kinesin KIF20A in GBM stem/progenitor cells.
- To determine if KIF20A inhibition can induce differentiation and suppress proliferation in GBM.
- To establish KIF20A as a potential target for differentiation-based GBM treatment.
Main Methods:
- Utilized complementary in vitro (2D cultures, 3D organoids) and in vivo (intracranial xenografts) models of GBM.
- Investigated the role of KIF20A, a key component of the cytokinetic machinery, in GBM stem/progenitor cell fate.
- Assessed the effects of KIF20A inhibition on cell cycle exit, differentiation, and proliferation.
Main Results:
- Inhibition of KIF20A was shown to drive GBM stem/progenitor cells to exit the cell cycle.
- KIF20A targeting induced a postmitotic/differentiated state in these cells.
- A marked suppression of proliferation was observed in GBM stem/progenitor cells following KIF20A inhibition.
Conclusions:
- KIF20A plays a critical role in maintaining the proliferative state of GBM stem/progenitor cells.
- Targeting KIF20A represents a promising strategy for differentiation-based therapy in glioblastoma.
- KIF20A is identified as a key vulnerability and a potential therapeutic target for GBM.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...